Hydroxychloroquine for COVID-19: A Single Center, Retrospective Cohort Study

{ 'indexed': {'date-parts': [[2023, 6, 6]], 'date-time': '2023-06-06T04:41:05Z', 'timestamp': 1686026465718}, 'reference-count': 27, 'publisher': 'Universiti Putra Malaysia', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 3, 13]]}, 'abstract': '<jats:p>Introduction: The outbreak of coronavirus disease (COVID-19) in December 2019 called ' 'for a rapid solution, leading to repurposing of existing drugs. Due to its immunomodulatory ' 'effect and antiviral properties, hydroxychloroquine (HCQ) has been used in early 2020 for ' 'treatment of COVID-19 patients. This study was conducted to evaluate the treatment outcome of ' 'HCQ monotherapy in Malaysia. Methods: A retrospective cohort study was conducted in COVID-19 ' 'ward in Hospital Kuala Lumpur (HKL), from March to April 2020. A total of 446 COVID-19 ' 'patients were recruited, only 325 patients were finally included for analysis. Statistical ' 'analysis was done using SPSS, with a significant value set at p&lt;0.05. Results: The mean ' 'age of the patients were 38.5 ±15.5. They were majority male, (n=210, 64.6%) Malaysian ' '(n=239, 73.5%) and Malay ethnicity (n=204, 62.8%). Ninety-one (28%) patients received HCQ ' 'monotherapy. HCQ monotherapy was associated with worse outcome (OR: 10.29, 95% CI ' '1.17-90.80). There was a significant difference in mean length of stay between those with and ' 'without HCQ treatment (t323=5.868, p&lt;0.001, 95% CI, 2.56-5.31). The average length of stay ' 'for HCQ treated group was 3.84 days longer than those without treatment. 6.6% of the patient ' 'receiving HCQ monotherapy encountered adverse drug effects. Conclusion: Similar to study ' 'reported worldwide, our study demonstrated that HCQ did not improve length of stay and the ' 'outcome of COVID-19 patients.</jats:p>', 'DOI': '10.47836/mjmhs.19.2.3', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 6]], 'date-time': '2023-06-06T00:26:56Z', 'timestamp': 1686011216000}, 'page': '8-13', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Hydroxychloroquine for COVID-19: A Single Center, Retrospective Cohort Study', 'prefix': '10.47836', 'volume': '19', 'author': [ {'given': 'Wen Chung', 'family': 'Ho', 'sequence': 'first', 'affiliation': []}, {'given': 'Xin Yong', 'family': 'Wei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khai Shin', 'family': 'Tan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yon Mak', 'family': 'Woh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mandeep Kaur', 'family': 'Gill', 'sequence': 'additional', 'affiliation': []}, {'given': 'Agnes Hui Ching', 'family': 'Lok', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shazwani', 'family': 'Zulkifli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Salmah', 'family': 'Idris', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khairil Erwan', 'family': 'Khalid', 'sequence': 'additional', 'affiliation': []}, {'given': 'Loon Leong', 'family': 'Chee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kang Nien', 'family': 'How', 'sequence': 'additional', 'affiliation': []}], 'member': '27687', 'published-online': {'date-parts': [[2023, 3, 13]]}, 'reference': [ { 'key': 'ref0', 'unstructured': '1. \tWorld Health Organization- WHO.WHO Coronavirus (COVID-19) ' 'Dashboard. Accessed on February 22 2022. Available from: ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019.'}, { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'unstructured': '2.\tWen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and ' 'safety of three new oral antiviral treatment (molnupiravir, fluvoxamine ' 'and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine. ' '2022;54:1516523. doi: 10.1080/07853890.2022.2034936.', 'DOI': '10.1080/07853890.2022.2034936'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'unstructured': '3.\tMaciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker ' 'DP, et al. A Review of the Preclinical and Clinical Efficacy of ' 'Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments ' 'against COVID-19. SLAS Discov. 2020;25(10):1108-1122. doi: ' '10.1177/2472555220958385.', 'DOI': '10.1177/2472555220958385'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'unstructured': '4.\tAbolghasemi E, Moosa-Kazemi SH, Davoudi M, Reisi A, Satvat MT. ' 'Comparative study of chloroquine and quinine on malaria rodents and ' 'their effects on the mouse testis. Asian Pac J Trop Biomed. ' '2012;2:311–314. doi: 10.1016/S2221-1691(12)60030-6.', 'DOI': '10.1016/s2221-1691(12)60030-6'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'unstructured': '5.\tMisra D, Gasparyan A.Y, Zimba O. Benefits and adverse effects of ' 'hydroxychloroquine, methotrexate and colchicine: searching for ' 'repurposable drug candidates. Rheumatol Int. 2020;40:1741–1751. doi: ' '10.1007/s00296-020-04694-2.', 'DOI': '10.1007/s00296-020-04694-2'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'unstructured': '6.\tShimizu Y, Yamamoto S, Homma M, Ishida N. Effect of chloroquine on ' 'the growth of animal viruses. Arch Gesamte Virusforsch. ' '1972;36(1):93-104. doi: 10.1007/BF01250299.', 'DOI': '10.1007/bf01250299'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'unstructured': '7.\tWang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and ' 'chloroquine effectively inhibit the recently emerged novel coronavirus ' '(2019-nCoV) in vitro. Cell Res 2020;30:269-271. ' 'doi:10.1038/s41422-020-0282-0.', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'unstructured': '8.\tYao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro ' 'antiviral activity and projection of optimized dosing design of ' 'hydroxychloroquine for the treatment of Severe Acute Respiratory ' 'Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. ' '2020;71(15):732-739. doi: 10.1093/cid/ciaa237.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'unstructured': '9.\tLiu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. ' 'Hydroxychloroquine, a less toxic derivative of chloroquine, is effective ' 'in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. ' 'doi: 10.1038/s41421-020-0156-0.', 'DOI': '10.1038/s41421-020-0156-0'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'unstructured': '10.\tGautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et ' 'al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: ' 'results of an open-label non-randomized clinical trial. Int J Antimicrob ' 'Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'unstructured': '11.\tGautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, et ' 'al. Clinical and microbiological effect of a combination of ' 'hydroxychloroquine and azithromycin in 80 COVID-19 patients with at ' 'least a six-day follow up: A pilot observational study. Travel Med ' 'Infect Dis. 2020;34:101663. doi: 10.1016/j.tmaid.2020.101663.', 'DOI': '10.1016/j.tmaid.2020.101663'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'unstructured': '12.\tChen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of ' 'hydroxychloroquine in patients with COVID-19: results of a randomized ' 'clinical trial. MedRxiv. 2020;03.22.20040758. doi: ' '10.1101/2020.03.22.20040758', 'DOI': '10.1101/2020.03.22.20040758'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'unstructured': '13.\tWHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, ' 'Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed ' 'Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N ' 'Engl J Med. 2021;384(6):497-511. doi: 10.1056/NEJMoa2023184.', 'DOI': '10.1056/nejmoa2023184'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'unstructured': '14.\tRECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell ' 'JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in ' 'Hospitalized Patients with Covid-19. N Engl J Med. ' '2020;383(21):2030-2040. doi: 10.1056/NEJMoa2022926.', 'DOI': '10.1056/nejmoa2022926'}, { 'key': 'ref14', 'doi-asserted-by': 'crossref', 'unstructured': '15.\tAxfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo ' 'EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in ' 'Covid-19: an international collaborative meta-analysis of randomized ' 'trials. Nat Commun. 2021;12(1):2349. doi: 10.1038/s41467-021-22446-z.', 'DOI': '10.1038/s41467-021-22446-z'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'unstructured': '16.\tCoronavirus (COVID-19) Update: FDA revokes emergency use ' 'authorization for chloroquine and hydroxychloroquine. Published June 15 ' '2020. Accessed on February 22 2022. Available from: ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and#:~:text=Today%2C%20the%20U.S.%20Food%20and,clinical%20trial%20was%20unavailable%2C%20or', 'DOI': '10.1089/clinomi.08.02.12'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'unstructured': '17.\tCOVID-19 management guidelines in Malaysia No 5/2020. Annex 2e. ' 'Clinical management of confirmed COVID-19 case in adult and paediatric. ' 'Published August 13 2021. Accessed on February 22 2022. Available from: ' 'https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX_2e_CLINICAL_MANAGEMENT_OF_CONFIRMED_COVID-19_CASE_IN_ADULT_AND_PAEDIATRIC_13082021.pdf', 'DOI': '10.11113/umran2021.8n2.489'}, { 'key': 'ref17', 'doi-asserted-by': 'crossref', 'unstructured': '18.\tHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical ' 'features of patients infected with 2019 novel coronavirus in Wuhan, ' 'China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.', 'DOI': '10.1016/S0140-6736(20)30183-5'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'unstructured': '19.\tOrnstein MH, Sperber K. The antiinflammatory and antiviral effects ' 'of hydroxychloroquine in two patients with acquired immunodeficiency ' 'syndrome and active inflammatory arthritis. Arthritis Rheum. ' '1996;39(1):157-61. doi: 10.1002/art.1780390122.', 'DOI': '10.1002/art.1780390122'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'unstructured': '20.\tBiran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab ' 'among intensive care unit COVID-19 patients: a multi-center ' 'observational study. Lancet Rheumatol. 2020;2(10):e603-e612. doi: ' '10.1016/S2665-9913(20)30277-0.', 'DOI': '10.1016/s2665-9913(20)30277-0'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'unstructured': '21.\tRECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham ' 'M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients ' 'with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: ' '10.1056/NEJMoa2021436.', 'DOI': '10.1056/nejmoa2021436'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'unstructured': '22.\tLadapo JA, McKinnon JE, McCullough PA, Risch H. Randomized ' 'controlled trials of early ambulatory hydroxychloroquine in the ' 'prevention of COVID-19 infection, hospitalization, and death: ' 'meta-analysis. medRxiv. 2020.09.30.20204693; doi: ' '10.1101/2020.09.30.20204693', 'DOI': '10.1101/2020.09.30.20204693'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'unstructured': '23.\tSrinivasa A, Tosounidou S, Gordon C. Increased incidence of ' 'gastrointestinal side effects in patients taking hydroxychloroquine: A ' 'brand-related issue? J Rheumatol. 2017;44(3):398. doi: ' '10.3899/jrheum.161063.', 'DOI': '10.3899/jrheum.161063'}, { 'key': 'ref23', 'doi-asserted-by': 'crossref', 'unstructured': '24.\tZhang J, Garrett S, Sun J. Gastrointestinal symptoms, ' 'pathophysiology, and treatment in COVID-19. Genes Dis. ' '2021;8(4):385-400. doi: 10.1016/j.gendis.2020.08.013.', 'DOI': '10.1016/j.gendis.2020.08.013'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'unstructured': '25.\tCostedoat-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lechat P, ' 'Funck-Brentano C et al. Heart conduction disorders related to ' 'antimalarials toxicity: An analysis of electrocardiograms in 85 patients ' 'treated with hydroxychloroquine for connective tissue diseases. ' 'Rheumatology. 2007;46(5):808–10. doi: 10.1093/rheumatology/kel402.', 'DOI': '10.1093/rheumatology/kel402'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'unstructured': '26.\t.Schrezenmeier E, Dörner T. Mechanisms of action of ' 'hydroxychloroquine and chloroquine: Implications for rheumatology. Nat ' 'Rev Rheumatol. 2020;16(3):155–66. doi: 10.1038/s41584-020-0372-x.', 'DOI': '10.1038/s41584-020-0372-x'}, { 'key': 'ref26', 'unstructured': '27.\tRismanbaf A, Zarei S. Liver and Kidney Injuries in COVID-19 and ' 'Their Effects on Drug Therapy; a Letter to Editor. Arch Acad Emerg Med. ' '2020;8(1):e17. Avilable from: ' 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075271/pdf/aaem-8-e17.pdf.'}], 'container-title': 'MARCH 2023', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2023, 6, 6]], 'date-time': '2023-06-06T00:28:16Z', 'timestamp': 1686011296000}, 'score': 1, 'resource': {'primary': {'URL': 'https://medic.upm.edu.my/upload/dokumen/2023032211275502_MJMHS_0551.pdf'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 3, 13]]}, 'references-count': 27, 'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2023, 3, 15]]}}, 'URL': 'http://dx.doi.org/10.47836/mjmhs.19.2.3', 'relation': {}, 'ISSN': ['1675-8544', '2636-9346'], 'subject': [], 'container-title-short': 'MJMHS', 'published': {'date-parts': [[2023, 3, 13]]}}